PubMed Health⌕ Search

PubMed · 8545344

[Prostate-specific antigen or PSA. Facts and probabilities].

Abstract

The introduction of prostatic specific antigen (PSA) assay as an organ-specific marker has totally modified our approach to diseases of the prostate gland. PSA is an exocrine secretion of the normal epithelium of the prostate and any infectious, dystrophic or tumoural processes involving the gland can lead to an increased level in the blood stream. PSA is the most effective means of following the curative effect of treatment for prostate cancer. After radical prostatectomy, PSA should be undetectable with hypersensitive tests (detection threshold < 0.1 ng/ml) 6 weeks after the operation. The persistence or reappearance of the marker in the blood stream is a clear indication of recurrence. A drop off in PSA under laboratory normal levels is an effective marker of the efficacy of hormone treatment for metastatic cancer but does not signify cure. There are still several points of debate. Serum PSA does increase with prostate volume but there is no apparent linear relationship. PSA is an important factor in early diagnosis of prostate cancer but must always be interpreted in light of the patient's age. In patients treated for cancer of the prostate, PSA is insufficient to determine tumour extension. The relationship between the PSA level and prostate volume could be a way of suspecting cancer, but the operator-dependent results of echography hinder application. Finally, search for circulating secretory cells with reverse transcriptase polymerase chain reactions still requires validation, but could be used for assessing cancer extension.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Boccon-Gibod. 1995-10-28. [Prostate-specific antigen or PSA. Facts and probabilities].. https://pubmed.ncbi.nlm.nih.gov/8545344/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗